Evidence map›Paper›PMID 42561949›Full record

Trial reportCell reports. Medicine2026

Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.

Jun-Jie Li, Lin-Xiaoxi Ma, Peng Ji, Li Chen, Jiong Wu, Guang-Yu Liu, Yi-Feng Hou, Gen-Hong Di, Zhen Hu, Yi-Zhou Jiang and 4 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05582499 (Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05582499 phase2recruitingnot on this map

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

TypeinterventionalSponsorFudan UniversityRan2022 to 2029Enrolled716ConditionsBreast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC)ArmsDalpiciclib, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jun-Jie LiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: lijunjie_ronaldo@hotmail.com.
Lin-Xiaoxi MaDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Peng JiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Li ChenDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jiong WuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Guang-Yu LiuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yi-Feng HouDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Gen-Hong DiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhen HuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yi-Zhou JiangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lei FanDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhong-Hua WangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ke-Da YuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yukeda@fudan.edu.cn.
Zhi-Ming ShaoDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: zhimingshao@fudan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this phase 2 trial (NCT05582499), patients with stage II-III hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer were categorized into endocrine-based and targeted-based groups based on previously proposed similarity network fusion (SNF) subtyping by digital pathology classification and were then randomly assigned in a 1:1 ratio to receive precision or control treatment. The primary endpoint was pathological complete response (pCR). Among 251 randomized patients, 49 were classified into an endocrine-based group and 202 into a targeted-based group. Patients receiving precision treatment had a significantly higher pCR rate (11.1% [90% confidence interval (CI), 6.8-16.8] vs. 4.0% [90% CI, 1.6-8.2]; p = 0.033), with the benefit mainly derived from the targeted-based group (13.9% in precision vs. 4.0% in control; p = 0.026). Toxicity was manageable. Our findings highlight that guiding neoadjuvant precision treatment by SNF subtyping in patients with HR+/HER2- breast cancer showed potential clinical benefits, with improvement of pCR in the targeted-based group and better tolerance in the endocrine-based group.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyPrecision MedicineReceptors, EstrogenReceptors, ProgesteroneAdultAgedFemaleHumansMiddle AgedPathologic Complete ResponseTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteronebreast cancerHR+/HER2−neoadjuvantpathological complete responseprecision treatments

Identifiers

PMID42561949
PMCPMC13522783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.